… persist in the peripheral blood of CML patients in molecular response, including those in
treatment-free remission [… Furthermore, the BCR-ABL oncoprotein is known to promote cell cycle …

… of molecular response it is unclear why 50% of patients lose … [14, 15], but no direct evidence
has been presented. An … that in patients in a stringently defined TFR (persistent UMR4.…

… Early evidence for the role of the immune response in TFR … a larger number of patients to
remain in therapy-free remission after … of LSC persistence and the cellular and molecular factors …

… However, evidence of persistent or recurrent MRD was … A molecular response was
documented in 80% of the patients, … Notably, 5 patients remained in long-term remission without …

… The BCR-ABL tyrosine kinase … patients with persistent DMR. It turns out that in the
restoration of immune control over the leukemic clone, there is a depth of the molecular response …

… on the persistence of quiescent LSC in patients with CML … to identify patients at elevated risk
for molecular response loss … leukaemia patients with undetectable BCR-ABL transcript level…

… in whom BCR::ABL1 transcripts were not detected for >2 … TFR in patients with a deep
molecular response (DMR) … Based on this evidence, a durable, deep response is a significantly …

… Physicians and patients are rightly delighted with an … TKIs achieve deeper molecular
remissions increasing the … In conclusion, we suggest the persistence of haematopoietic stem cells …

… for patients aiming to achieve treatment-free remission and a … % at any time as the optimal
response for patients aiming for … A stable molecular response was defined as persistence of …

… in human BCR-ABL + CD34 + CD38 − cells and that CML … number of patients were evaluable
for molecular response during … is minimal in cells that persist in patients responding to TKIs …